Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05898009 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2

Study acronym: CanSeR-OGen
StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Mar 22, 2025 to May 21, 2026 Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial status changed: Unknown → Completed
    • Final enrollment: 228 participants (planned 300)
    • Eligibility criteria expanded, about 6 words
    • Site details revised
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Trial status: Not Yet Recruiting to Unknown
    • Start date changed from estimate of Aug 22, 2023 to Oct 19, 2023
    v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In mainland France, breast cancer is the most common cancer in women, with an estimated incidence of over 58,000 new cases. Even if breast cancer is a cancer with a good prognosis, it is responsible for more than 12,000 deaths per year (first cause of death by cancer in women in France). Breast cancer is a multifactorial disease, which results from the interaction between environmental, lifestyle, hormonal and genetic risk factors. In Reunion, more than 400 cases of breast cancer are diagnosed annually. As in mainland France, it is by far the most common cancer in Reunionese women, and its incidence continues to increase significantly since the age-standardized incidence rate increased by 28% between 2007 and 2017 to establish at 64.2/100,000 AP. Two studies carried out in patients carrying mutations in the breast-ovary predisposition genes in Reunion, showed that more than 50% of patients carrying BRCA mutation have a mutation specific to the Reunion population on the BRCA2 gene. These two studies, which confirm the genetic specificities of Reunion already described in other pathologies (Mucoviscidosis or Friedreich's Ataxia), suggest that this mutation could have a significant frequency in patients with breast cancer. Thus, evaluating the prevalence of this mutation in patients with breast cancer in Réunion would make it possible to adapt the indications for access to the oncogenetics consultation and the associated preventive measures
Trial Details
NCT Number NCT05898009
Lead Sponsor Centre Hospitalier Universitaire de la Réunion
Conditions
(from sponsor)
Breast Cancer, Genetic Disease, BRCA2 Mutation
Related terms Breast Neoplasms, Genetic Diseases, Inborn
Enrollment 228 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov